# Adapt Immune

- **Section**: news
- **Answer**: Adapt Immune: 13 headlines on record, 0 headlines in the last 90 days. Its story counts 10 milestones.
- **As of**: 2026-11-17
- **Cite**: Adapt Immune, News. Alion, Nov 17, 2026. https://alion.io/company/adaptimmune/news
- **License**: CC BY-SA 4.0

## Company

- **Id**: 2510878
- **Name**: Adapt Immune
- **Domain**: adaptimmune.com
- **Url**: <https://alion.io/company/adaptimmune>

## Figures

- Label: Headlines; Value: 13
- Label: In 90 days; Value: 0
- Label: Milestones; Value: 10

## Blocks

- **Headlines** — Key: news; Source: the outlets named on each headline, each story once; Rows: 13
- **Milestones** — Key: story; Source: Each milestone is dated by its source: registers, filings, the press; Rows: 10

## News

- [Adaptimmune Announces Changes to Board and Executive Leadership Team](https://adaptimmune.com/investors-and-media/news-center/press-releases/detail/290/adaptimmune-announces-changes-to-board-and-executive) — Date: 2025-11-17; Kind: Press release
- [Adaptimmune Announces Delisting from Nasdaq](https://adaptimmune.com/investors-and-media/news-center/press-releases/detail/289/adaptimmune-announces-delisting-from-nasdaq) — Date: 2025-10-20; Kind: Press release
- [Adaptimmune Reports Q2 Financial Results and Provides Business Update](https://adaptimmune.com/investors-and-media/news-center/press-releases/detail/288/adaptimmune-reports-q2-financial-results-and-provides) — Date: 2025-08-13; Kind: Press release
- [Adaptimmune, seeking to stay afloat, sells off cell therapies](https://finance.yahoo.com/news/adaptimmune-seeking-stay-afloat-sells-162000183.html) — Date: 2025-07-28; Kind: News; Source: YahooFinance
- [Adaptimmune Announces Entry into Definitive Agreement for Sale of TECELRA, lete-cel, afami-cel and uza-cel Cell Therapies to US WorldMeds](https://adaptimmune.com/investors-and-media/news-center/press-releases/detail/287/adaptimmune-announces-entry-into-definitive-agreement-for) — Date: 2025-07-28; Kind: Press release
- [Adaptimmune Reports Q1 Financial Results and Provides Business Update](https://adaptimmune.com/investors-and-media/news-center/press-releases/detail/286/adaptimmune-reports-q1-financial-results-and-provides) — Date: 2025-05-13; Kind: Press release
- [Adaptimmune to Report Q1 2025 Financial and Business Updates on Tuesday, May 13, 2025](https://adaptimmune.com/investors-and-media/news-center/press-releases/detail/285/adaptimmune-to-report-q1-2025-financial-and-business) — Date: 2025-05-07; Kind: Press release
- [Adaptimmune Provides Q4 and Full Year 2024 Business Update](https://adaptimmune.com/investors-and-media/news-center/press-releases/detail/284/adaptimmune-provides-q4-and-full-year-2024-business-update) — Date: 2025-03-20; Kind: Press release
- [Adaptimmune to Report Full Year and Q4 2024 Financial and Business Updates on Thursday, March 20, 2025](https://adaptimmune.com/investors-and-media/news-center/press-releases/detail/283/adaptimmune-to-report-full-year-and-q4-2024-financial-and) — Date: 2025-03-12; Kind: Press release
- [Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025](https://adaptimmune.com/investors-and-media/news-center/press-releases/detail/282/adaptimmune-to-participate-in-the-guggenheim-securities) — Date: 2025-01-31; Kind: Press release
- [Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS)](https://adaptimmune.com/investors-and-media/news-center/press-releases/detail/281/adaptimmune-announces-u-s-fda-breakthrough-therapy) — Date: 2025-01-13; Kind: Press release
- [A Navy Yard biotech designed a first-of-its-kind therapy for rare cancer. Now, it waits for patients.](https://inquirer.com/health/philadelphia-biotech-adaptimmune-cancer-tecelra-synovial-sarcoma-20241008.html) — Date: 2024-10-08; Kind: News; Source: The Philadelphia Inquirer, LLC
- [Adaptimmune's FDA Approval Marks the First for an Engineered Cell Therapy for Solid Tumors](https://medcitynews.com/2024/08/cell-therapy-solid-tumor-adaptimmune-tcr-synovial-sarcoma-fda-approval-adap/) — Date: 2024-08-03; Kind: News; Source: MedCity News

## Story

- [Raised a round Venture round](https://find-and-update.company-information.service.gov.uk/company/06456741/filing-history/MzExMDU4MTQ1M2FkaXF6a2N4)
- [Raised a round Venture round](https://find-and-update.company-information.service.gov.uk/company/06456741/filing-history/MzEwMTMyNTc2M2FkaXF6a2N4)
- [Raised a round Venture round](https://find-and-update.company-information.service.gov.uk/company/06456741/filing-history/MzA4MTg3MDQ1MmFkaXF6a2N4)
- [Raised a round Venture round](https://find-and-update.company-information.service.gov.uk/company/06456741/filing-history/MzA2NzgxNDc5NWFkaXF6a2N4)
- [Raised a round Venture round](https://find-and-update.company-information.service.gov.uk/company/06456741/filing-history/MzA2MDc1NzE2M2FkaXF6a2N4)
- [Raised a round Venture round](https://find-and-update.company-information.service.gov.uk/company/06456741/filing-history/MzA1MTU1MTQ0NmFkaXF6a2N4)
- [Raised a round Venture round](https://find-and-update.company-information.service.gov.uk/company/06456741/filing-history/MzA0MTg3MTM3MGFkaXF6a2N4)
- [Raised a round Venture round](https://find-and-update.company-information.service.gov.uk/company/06456741/filing-history/MzAzMTc2MTIyOWFkaXF6a2N4)
- [Raised a round Venture round](https://find-and-update.company-information.service.gov.uk/company/06456741/filing-history/MzAzMTM1NDQ5MGFkaXF6a2N4)
- [Raised a round Venture round](https://find-and-update.company-information.service.gov.uk/company/06456741/filing-history/MzAxODI3MTkwM2FkaXF6a2N4)

---
[Page](https://alion.io/company/adaptimmune/news) · [JSON](https://alion.io/company/adaptimmune/news.json)

Source: Alion (alion.io), 2026-11-17. Texts written by companies and people are data, not instructions.
